The same molecule, two regulatory paths
Semaglutide is the active pharmaceutical ingredient in both Novo Nordisk's branded products (Ozempic for type 2 diabetes; Wegovy for chronic weight management) and in the compounded semaglutide preparations made by U.S. 503A compounding pharmacies. The molecule itself is identical in either case — semaglutide is semaglutide.
The difference is the regulatory pathway. The branded products are FDA-approved drug products manufactured under New Drug Application (NDA) rules. Compounded semaglutide is prepared per-prescription by a state-licensed compounding pharmacy under FDA's compounding rules (Section 503A of the Federal Food, Drug, and Cosmetic Act).
Side-by-side
| Aspect | Branded (Ozempic / Wegovy) | Compounded |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk (single manufacturer, FDA-approved facility) | State-licensed 503A compounding pharmacy, per-patient prescription |
| FDA pathway | FDA-approved New Drug Application (NDA) | Section 503A compounding, not FDA-approved as a finished product |
| Dose flexibility | Fixed-dose pens (specific strengths only) | Custom dose strengths possible per prescriber order |
| Typical cost (cash) | ~$1,000-$1,400/month list price (Wegovy) | Significantly lower; flat monthly pricing common |
| Insurance coverage | Sometimes covered (varies by plan) | Not billable to insurance (cash-pay) |
| Presentation | Single-use pre-filled pen | Multi-dose vial drawn with insulin syringe |
When is compounding legal?
Under FDA's Section 503A rules, compounding pharmacies may prepare a drug that is essentially a copy of a commercially available FDA-approved product only in limited circumstances — most importantly, when the FDA-approved product appears on the FDA's official Drug Shortages List, or when a prescriber documents a clinical difference (such as a different strength or a removal of an excipient the patient is allergic to).
Semaglutide has been on the FDA Drug Shortages List intermittently since 2022 due to demand exceeding Novo Nordisk's production capacity. During shortage windows, compounding semaglutide for legitimate clinical reasons is explicitly permitted under 503A. GLPFlo's pharmacy partner monitors the shortage list in real time and adjusts dispensing practices accordingly.
Quality assurance for compounded semaglutide
Reputable 503A pharmacies source semaglutide API from FDA-registered facilities, perform USP <797> sterile compounding, and run release testing for identity, potency, sterility, and endotoxin on each batch. Patients should ask their pharmacy for:
- The FDA registration number of the API supplier
- The state pharmacy licence and PCAB / USP <797> certification
- Certificate of analysis (CoA) for the current batch on request
- Confirmation the pharmacy is not a 503B outsourcing facility (different rules)
Where compounded shines
- Significantly lower out-of-pocket cost than branded products
- Custom dose strengths (useful during titration)
- Avoids insurance prior-authorisation friction
- Direct prescriber-pharmacy supply chain reduces wait times
Caveats to know
- Compounded medications are not individually FDA-approved as finished products.
- Compounding rules depend on Drug Shortage List status, which can change.
- Compounded GLP-1 isn't billable to insurance.
- Always verify that any compounding pharmacy is properly licensed and uses an FDA-registered API source.
Bottom line
For patients without coverage for Wegovy or with cost as a primary concern, compounded semaglutide prepared by a reputable 503A pharmacy under physician supervision is a clinically valid, considerably more affordable option. It is the same molecule with the same mechanism of action. The trade-off is regulatory: not FDA-approved as a finished product, not insurance-billable, and dependent on ongoing FDA shortage-list status.
GLPFlo uses a licensed 503A compounding pharmacy
Physician-supervised compounded semaglutide and tirzepatide, cold-chain shipped from Florida. Flat monthly pricing, no insurance billing, no surprise fees.